Organisms | Evidence |
---|---|
Ovis aries (sheep) | |
Cricetulus griseus (Chinese hamster) | |
Mus musculus (house mouse) | |
Bos taurus (domestic cattle) | |
Escherichia coli |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
Pathway Name | Organism |
---|---|
E.coli O101 | Escherichia coli |
E.coli O103 | Escherichia coli |
E.coli O107 | Escherichia coli |
E.coli O112ab | Escherichia coli |
E.coli O112ac | Escherichia coli |
E.coli O116 | Escherichia coli |
E.coli O117 | Escherichia coli |
E.coli O125ab | Escherichia coli |
E.coli O127 | Escherichia coli |
E.coli O128ab-H27 | Escherichia coli |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
33767387 | LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation | Ahn G | 2021 Mar 25 |
|
33815292 | New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect | Dias JA | 2021 Mar 19 |
|
33724805 | Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to GalNAc and the Tumor-Associated Tn Antigen | Gabba A | 2021 Mar 16 |
|
33581419 | Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran | Steinberg T | 2021 Mar 15 |
|
33691403 | Discovery of Bivalent GalNAc-Conjugated Betulin as a Potent ASGPR-Directed Agent against Hepatocellular Carcinoma | Yamansarov EY | 2021 Mar 11 |
|
33658366 | Architecturally complex O -glycopeptidases are customized for mucin recognition and hydrolysis | Pluvinage B | 2021 Mar 03 |
|
33746941 | Soluble N-Acetylgalactosamine-Modified Antigens Enhance Hepatocyte-Dependent Antigen Cross-Presentation and Result in Antigen-Specific CD8+ T Cell Tolerance Development | Damo M | 2021 Mar 03 |
|
33878355 | A N-acetyl-D-galactosamine-binding lectin from Amaranthus gangeticus seeds inhibits biofilm formation and Ehrlich ascites carcinoma cell growth in vivo in mice | Hasan I | 2021 Jun 30 |
|
34184789 | Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta‐synthase | Vassiliou D | 2021 Jun 29 |
|
34145602 | Acute intermittent porphyria, givosiran, and homocysteine | Fontanellas A | 2021 Jun 22 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025